The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in Ehrlich ascites tumor-bearing mice

Cancer Biology and Therapy

Volumn 4, Issue 1, 2005, Pages 94-101

  Gupta, Seema ^a,c   Mathur, Rohit ^a,b   Dwarakanath, B S ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b UNIVERSITY OF DELHI   (India)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

2 deoxy D glucose; Chemotherapy; EAT; Etoposide; Normal tissue toxicity; Topoisomerase poison

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYGLUCOSE; ETOPOSIDE; FYTOSID; ANTIMETABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASCITES FLUID; ASCITES TUMOR; BODY WEIGHT; BONE MARROW; CANCER CONTROL; CANCER SURVIVAL; CELL ACTIVITY; CELL CYCLE; CELL DEATH; CELL GROWTH; CELL STRUCTURE; CELL SURVIVAL; CELLULAR PARAMETERS; CONTROLLED STUDY; CONVALESCENCE; CYTOGENETICS; DNA CONTENT; DRUG EFFECT; DRUG POTENTIATION; EHRLICH ASCITES TUMOR; FLOW CYTOMETRY; FOLLOW UP; GENETIC DAMAGE; GLYCOLYSIS; MALE; MICRONUCLEUS TEST; MOUSE; NONHUMAN; SOLID TUMOR; SPLEEN INJURY; STATISTICAL SIGNIFICANCE; TISSUE INJURY; TOXICITY; TUMOR GROWTH; ANIMAL; CELL PROLIFERATION; DNA DAMAGE; DRUG INTERACTION; EXPERIMENTAL NEOPLASM; PATHOLOGY;

ANIMALS; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, EHRLICH TUMOR; CELL CYCLE; CELL PROLIFERATION; DEOXYGLUCOSE; DNA DAMAGE; DRUG INTERACTIONS; ETOPOSIDE; MICE; NEOPLASMS, EXPERIMENTAL;

EID: 24644489711     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.1.1381     Document Type: Article

References (67)

1. Wang JC. DNA topoisomerases. Ann Rev Biochem 1996; 65:635-92.
2. Champoux JJ. DNA topoisomerases: Structure, function and mechanism. Ann Rev Biochem 2000; 369-413.
3. Verga-Welsz PD, Wilm M, Bonte E, Dumas K, Mann M, Becker PB. Chromatin remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II. Nature 1997; 388:593-602.
4. Issacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ, Hickson ID. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1998; 1400:121-37.
5. Holm C, Covey JM, Kerrigan D, Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989; 49:6365-70.
6. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260:14873-5.
7. Lambert JM, Fernandes DJ. Topoisomerase II cleavable complex formation within DNA loop domains. Biochem Pharmacol 2000; 60:101-9.
8. Davies SM, Robson CN, Davies SL, Hickson ID. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 1988; 263:17724-9.
9. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, Hickson ID. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991; 51:6592-5.
10. Chen AY, Liu LF. DNA topoisomerases: Essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 1994; 34:191-218.
11. Sinha BK. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 1995; 49:11-9.
12. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1998; 1400:155-71.
13. Hussain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I and mRNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994; 54:539-46.
14. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: Inhibition of DNA religation by etoposide. Biochemistry 1980; 28:6157-60.
15. Ross W, Rowe T, Glisson B, Yalowich J, Liu L. Role of topoisomerase II in mediating epipodophyllotoxin induced DNA cleavage. Cancer Res 1984; 44:5857-60.
16. Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 1973; 33:2834-46.
17. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M. DNA topoisomerase I - targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246:1046-8.
18. Giovanella BC, Hinz HR, Koziiski AJ, Stelin Jr JS, Silber R, Potmesil M. Complete growth inhibition of human cancer xenograft in nude mice treatment with 20-(S)-camptothecin. Cancer Res 1991; 51:3352-5.
19. Giaccone G, Ark-Otte JV, Scagliotti G, Capranico G, Valk PV, Rubio G, Dalesio O, Lopez R, Zunino F, Walboomers J, Pinedo HM. Differential experience of DNA topoisomerase in non -small cell lung cancer and normal lung. Biochim Biophys Acta 1995; 64:337-46.
20. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP dependent transporters. Nature 2002; 2:48-58.
21. Schuurhuis GJ, Broxterman HJ, De Lange JH, Pinedo HM, Van Heijningen TH, Kuiper CM, Scheffer GL, Scheper RJ, Van Kalken CK, Baak JP, et al. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer 1991; 64:857-61.
22. Gervasoni Jr JE, Taub RN, Rosado M, Krishna S, Stewart VJ, Knowles DM, Bhalla K, Ross DD, Baker MA, Lutzky J, et al. Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells. Cancer Chemother Pharmacol 1991; 28:93-101.
23. Subramanian D, Rosenstein BS, Muller MT. Ultraviolet induced DNA damage stimulates topoisomerase I-DNA complex formation in vivo: Possible relationship with DNA repair. Cancer Res 1998; 58:976-84.
24. Gillano N, Ikhtiar AM, Malinovski OV. The effects of inhibitors of DNA topoisomerase II on the radiosensitivity, repair and conformational changes in the chromatin in mammalian cells. Radiobiologia 1993; 33:189-96.
25. Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1998; 1400:173-84.
26. Larsen AK, Skladanowski A. Cellular resistance to topoisomerase-targeted drugs: From drug uptake to cell death. Biochim Biophys Acta 1998; 1400:257-74.
27. Dingemans AC, Pinedo HM, Giaccone G. Clinical resistance to topoisomerase targeted drugs. Biochim Biophys Acta 1998; 1400:275-88.
28. Stine KC, Saylors RL, Sawyer JR, Becton DL. Secondary acute myelogenous leukemia following safe exposure to etoposide. J Clin Oncol 1997; 15:1583-6.
29. Dwarakanath BS, Mathew TL. Approaches for improving cancer chemotherapy using topoisomerase inhibitors. Chennai: XXII Annual Conference of Indian Association of Biomedical Scientists, 2001.
30. Dwarakanath BS, Adhikari JS, Khaitan D, Mathew TL, Jain V. Modification of cellular response to topoisomerase inhibitor for improving cancer therapy. Chennai: XV Asia Pacific Cancer Conference, 1999.
31. Dwarakanath BS, Khaitan D, Singh S, Mathew TL, Jain V. Two-Deoxy-D-glucose enhances the cytotoxic effects of topoisomerase inhibitors in Human Tumor Cell Lines. Bangalore: IUBMB Symposium on DNA Enzymes: Structure & Mechanisms, 2000.
32. Dwarakanath BS, Khaitan D, Mathur R. Inhibitors of Topoisomerases as anticancer drugs: Problems and Prospects. Ind J Expt Biol 2004; 42:649-59.
33. Jha B, Pohlit W. Effect of 2-deoxy-D-glucose on DNA double strand repair, cell survival and energy metabolism in euoxic Ehrlich ascites tumor cells. Int J Radiat Biol 1992; 62:409-15.
34. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental oncology. Br J Cancer 1998; 77:1-10.
35. Dwarakanath BS, Jain V. Enhancement of the radiation-induced damage by 2-deoxy-D-glucose in organ cultures of brain tumors. Ind J Med Res 1985; 82:266-8.
36. Countryman PI, Heddle JA. Production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. Mutat Res 1976; 41:321-32.
37. Dwarakanath BS, Jain V Energy linked modifications of the radiation response in a human glioma cell line. Int J Radiat Oncol Biol Phys 1989; 17:1033-40.
38. Yanagihara K, Nii M, Kamiya KN, Tauchi H, Sawada S, Seito S. Radiation-induced apoptotic cell death in human gastric epithelial tumor cells: Correlation between mitotic death and apoptosis. Int J Radiat Biol 1995; 77:677-685.
39. Dwarakanath BS, Adhikari JS, Jain V. Hematoporphyrin derivatives potentiate the radiosensitizing effects of 2-deoxy-D-glucose in Cancer cells. Int J Radiat Oncol Biol Phys 1999; 43:1125-33.
40. Dwarakanath BS, Zolzer F, Adhikari JS, Streffer C, Jain VK. 2-deoxy-D-glucose induced modifications of proliferation kinetics and radiation induced division delay in human tumor cells in vitro: Recent aspects of cellular and applied radiobiology. Forschungszentrum Julich GmbH, Germany edited by FHA Schineeweiss and RN Sharan 1999.
41. O'Dwyer PJ, Jones BL, Alonso MT, Marsoni S, Wittes RE. Etoposide (VP-16-213). Current status of an active anticancer drug. New Engl J Med 1985; 312:692-700.
42. Baguley BC, Ferguson LR. Mutagenic properties of topoisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400:213-22.
43. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259:13560-6.
44. Osheroff N. Biochemical basis for the interactions of Type 1 and Type II topoisomerases with DNA. Pharmacol Ther 1989; 41:223-41.
45. Nittis JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996; 32A:958-66.
46. Jain VK, Kalia VK, Sharma R, Maharajan V, Menon M. Effects of 2-deoxy-D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells. Int J Radiat Oncol Biol Phys 1985; 11:943-50.
47. Jain V, Pohlit W. Influence of energy metabolism on the repair of X-ray damage in living cells. III. Effect of 2-deoxy-D-glucose on the liquid holding reactivation in yeast. Biophysik 1973; 10:137.
48. Dwarakanath BS, Zolzer F, Chandna S, Bauch T, Adhikari JS, Muller WU, Streffer C, Jain V. Heterogeneity in 2-deoxy-D-glucose induced modifications in energetic and radiation responses of human tumor cell lines. Int J Radiat Oncol Biol Phys 2001; 51:1151-61.
49. Jain VK, Purohit SC, Pohlit W. Optimization of cancer therapy-Part I. Inhibition of repair of X-ray induced potentially lethal damage by 2-deoxy-D-glucose in Ehrlich ascites tumor cells. Ind J Expt Biol 1977; 15:711-3.
50. Waterhouse N, Kumar S, Song Q, Strike P, Sparrow L, Dreyfuss G, Alnemri ES, Litwack G, Lavin M, Watters D. Heteronuclear ribonucleoproteins C1 and C2, components of the spliceosome, are specific targets of interleukin 1beta-converting enzyme-like proteases in apoptosis. J Biol Chem 1996; 271:29335-41.
51. Martins LM, Kottke T, Mesner PW, Basi GS, Sinha S, Frigon Jr N, Tatar E, Tung JS, Bryant K, Takahashi A, Svingen PA, Madden BJ, McCormick DJ, Earnshaw WC, Kaufmann SH. Activation of multiple interleukin-1beta converting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposide-induced apoptosis. J Biol Chem 1997; 272:7421-30.
52. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note. Cancer Res 1989; 49:5870-8.
53. Gupta S, Mathur R, Dwarakanath BS. Modifications of etoposide induced toxicity by 2-deoxy-D-glucose in murine tumors. Biomedicine 2004; 24:31-44.
54. Sumner AT. Inhibitors of topoisomerase II delay progress through mitosis and induce a doubling of the DNA content in CHO cells. Expt Cell Res 1995; 217:440-7.
55. Zucker RM, Adams DJ, Bair KW, Elstein KH. Polyploidy induction as a consequence of topoisomerase inhibition. A flow cytometric assessment. Biochem Pharmacol 1991; 42:2199-208.
56. Ferguson LR, Whiteside G, Holdaway KM, Baguley BC. Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine. Environ Mol Mutagen 1996; 27:255-62.
57. Kallio M, Lahdetie J. Effects of the DNA topoisomerase II inhibitor merbarone in male mouse meiotic divisions in vivo: Cell cycle arrest and induction of aneuploidy. Environ Mol Mutagen 1997; 29:16-27
58. Deming PB, Cistulli CA, Zhao H, Graves PR, Piwnica-Worms H, Paules RS, Downes CS, Kaufmann WK. The human decatenation checkpoint. Proc Natl Acad Sci USA 2001; 98:12044-9.
59. Kalia VK, Jain VK, Otto FJ. Optimization of cancer therapy: Part IV- Effects of 2-deoxy-D-glucose on radiation induced chromosomal damage in PHA stimulated peripheral human leukocytes. Ind J Expt Biol 1982; 20:884-8.
60. Ramirez CD, Catchpoole DR. Etoposide-induced apoptosis in lymphoblastoid leukaemic MOLT-4 cells: Evidence that chromatin condensation, loss of phosphatidylserine asymmetry and apoptotic body formation can occur independently. Apoptosis 2002; 7:59-68.
61. Sumner AT. Inhibitors of topoisomerases do not block the passage of human lymphocyte chromosomes through mitosis. J Cell Sci 1992; 103:105-15.
62. 2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res 1995; 55:1509-16.
63. Kumarswamy R, Manickam J, Adhikari JS, Dwarakanath BS. The glycolytic inhibitor 2-deoxy-D-glucose does not enhance radiation induced apoptosis in mouse splenocytes and thymocytes in-vitro. JNU, Delhi: Emerging trends in cancer biology, 2002.
64. Singh SP, Singh S, Jain VK. Effects of 5-bromo-2-deoxyuridine and 2-deoxy-D-glucose on radiation induced micronuclei in mouse bone marrow. Int J Radiat Biol 1990; 85:791-7.
65. Singh D, Banerjee AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL, Ravindranath T, Jain V. Dose escalation studies with 2-deoxy-D-glucose as an adjuvant in the radiotherapy of glioblastoma multiforme. Int J Radiat Oncol Biol Phys communicated 2003.
66. Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, Chandramouli BA, Banerjee AK, Das S, Jena A, Ravichandran R, Sahi UP, Kumar R, Kapoor N, Kalia VK, Dwarakanath BS, Jain V. Improving cancer radiotherapy with 2-deoxy-D-glucose: Phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 1996; 35:103-11.
67. Dwarakanath BS, Mathew TL, Jain V. Experimental and clinical studies to improve the radiotherapy of human brain tumors. Biomedicine 2000; 20:73-86.